| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 2000: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1999: ¥2,400,000 (Direct Cost: ¥2,400,000)
|
|---|
| Research Abstract |
The lung cancer is a disease of poor prognosis, which shows the resistance for the treatment. The change of expression of p53 induced gene (PIG) as one of the causes of this refractory. In this study, it is made that lung cancer gene therapy that it clarified the change of the expression of the PIG gene cluster and gave in the beginning develops further to be a purpose. The tissue of the lung cancer collected via bronchoscope or operatively is cultured in 10%FCS RPMI with anti-cancer drugs such as CDDP, BLM and Pacritaxel for some periods. And examine whether p53 gene cluster is activated or not. The gene therapy, which introduced p53 into lung cancer of the patient by Adeno virus, was started in December, last year in our hospital. Description and agreement document to the patient were also being made. When this clinical research was started, the permission of the ethics committee was also obtained. Only few patients were proved the p53 gene abnormality in our institute until now. It is less than the frequency by the report ever since (about 50%). 51-year old man who suffered with lung carcinoma was given CDDP and Ad5CMV-p53. But he refused further any anti-cancer treatment, therefore the formal evaluation about tumor reduction effect was impossible. But the temporary tumor reduction effect was observed and his performance status did not change.
On the analysis of the PIG gene, many patients must be included. In future, we will do further effort.
|
